Legend Biotech Corporatio... (LEGN)

NASDAQ: LEGN · Real-Time Price · USD

34.00

-0.95 (-2.72%)

At close: May 01, 2025, 3:59 PM

34.61

1.79%

After-hours: May 01, 2025, 04:06 PM EDT

-2.72% (1D)

Bid	24.83
Market Cap	3.12B
Revenue (ttm)	627.24M
Net Income (ttm)	-177.03M
EPS (ttm)	-0.96
PE Ratio (ttm)	-35.42
Forward PE	65.87
Analyst	Buy

Ask	43.64
Volume	445,518
Avg. Volume (20D)	1,285,685
Open	34.55
Previous Close	34.95
Day's Range	33.97 - 34.91
52-Week Range	29.27 - 60.87
Beta	0.21

About LEGN

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refr...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 5, 2020

Employees 2,600

Stock Exchange NASDAQ

Ticker Symbol LEGN

Website https://www.legendbiotech.com

Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for LEGN stock is "Buy." The 12-month stock price forecast is $81.5, which is an increase of 139.71% from the latest price.

Stock Forecasts

Next Earnings Release

Legend Biotech Corporation is scheduled to release its earnings on May 13, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 month ago

+9.29%

Legend Biotech Corporation shares are trading high... Unlock content with Pro Subscription

3 months ago

+6.15%

Legend Biotech shares are trading higher. HC Wainwright & Co. reiterated a Buy rating on the stock.

News

2 weeks ago · zacks.com

Legend Biotech (LEGN) Moves 5.1% Higher: Will This Strength Last?

Legend Biotech (LEGN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more stre...

3 weeks ago · benzinga.com

Cell Therapy Maker Legend Biotech Is An 'Attractive Opportunity' Due To No Material Tariff Exposure: Analyst

With U.S. President Donald Trump's tariffs, HC Wainwright analyst writes that investors are looking for companies with macroeconomic moats that protect against tariff exposure and regulatory uncertain...

1 month ago · seekingalpha.com

Legend Biotech Corporation (LEGN) Q4 2024 Earnings Call Transcript

Legend Biotech Corporation (NASDAQ:LEGN ) Q4 2024 Earnings Conference Call March 11, 2025 8:00 AM ET Company Participants Caroline Paul - Associate Director, IR Ying Huang - CEO Jessie Yeung - Interim...